Skip to Content

BeiGene Ltd ADR BGNE

Morningstar Rating
$168.50 −1.50 (0.88%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BGNE is trading at a 13% discount.
Price
$170.95
Fair Value
$473.89
Uncertainty
High
1-Star Price
$927.81
5-Star Price
$713.62
Economic Moat
Mlgkn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BGNE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$170.00
Day Range
$168.33170.78
52-Week Range
$139.73272.49
Bid/Ask
$163.72 / $169.10
Market Cap
$17.60 Bil
Volume/Avg
154,842 / 282,087

Key Statistics

Price/Earnings (Normalized)
Price/Sales
7.15
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
10,000

Comparables

Valuation

Metric
BGNE
09688
09939
Price/Earnings (Normalized)
Price/Book Value
4.982.280.33
Price/Sales
7.156.75
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
BGNE
09688
09939
Quick Ratio
1.974.292.66
Current Ratio
2.324.634.89
Interest Coverage
−54.22
Quick Ratio
BGNE
09688
09939

Profitability

Metric
BGNE
09688
09939
Return on Assets (Normalized)
−8.47%−22.36%−29.60%
Return on Equity (Normalized)
−12.68%−26.78%−42.85%
Return on Invested Capital (Normalized)
−12.45%−30.45%−34.63%
Return on Assets
BGNE
09688
09939
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFvxt$595.3 Bil
VRTX
Vertex Pharmaceuticals IncNtqjr$106.3 Bil
REGN
Regeneron Pharmaceuticals IncTrplly$105.4 Bil
MRNA
Moderna IncMkqb$39.8 Bil
BNTX
BioNTech SE ADRFbnf$22.1 Bil
ARGX
argenx SE ADRFnm$21.5 Bil
ALNY
Alnylam Pharmaceuticals IncZrjvn$18.6 Bil
BMRN
Biomarin Pharmaceutical IncPxshqjt$15.8 Bil
RPRX
Royalty Pharma PLC Class AJgwyfy$13.4 Bil
INCY
Incyte CorpQkkfln$12.9 Bil

Sponsor Center